Skip to main content

No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.

Publication ,  Journal Article
Vaidyanathan, G; Zhao, XG; Strickland, DK; Zalutsky, MR
Published in: J Nucl Med
February 1997

UNLABELLED: The purpose of this study was to evaluate the properties of 4-fluoro-3-[131I]iodobenzylguanidine ([131I]FIBG), a potential neuroendocrine tumor and myocardial imaging radiopharmaceutical. METHODS: The binding of [131I]FIBG and [125I]MIBG was compared in vitro using the SK-N-SH human neuroblastoma cell line. The role of the active uptake-1 mechanism was investigated by determining the effect on cell binding of desipramine (DMI), ouabain, norepinephrine (NE), unlabeled MIBG and FIBG and by incubation at 4 degrees C. Finally, the tissue distributions of [131I]FIBG and [125I]MIBG were compared in normal mice. RESULTS: The specific binding of [131I]FIBG remained fairly constant (45%-60%) over a 2-3-log activity range and consistently was 11%-14% higher (p < 0.05) than that of [125I]MIBG. The uptake of [131I]FIBG was reduced to 13% of control values by 1.5 microM DMI, to 31% by 1 mM ouabain, to 8% by lower temperature, to 8% by 50 microM NE and to 6% and 5% by 10 microM each of unlabeled MIBG and FIBG, respectively. The amount of [131I]FIBG retained by SK-N-SH cells was significantly higher than that of [125I]MIBG with the maximum difference observed at 72 hr. In mice, the uptake of [131I]FIBG was higher than that of [125I]MIBG not only in target tissues (heart and adrenals) but also in many other normal tissues; conversely, thyroidal uptake of [131I]FIBG was 2-3-fold lower than that of [125I]MIBG. The uptake of [131I]FIBG in the heart and adrenals was reduced by DMI. CONCLUSION: Iodine-131-FIBG is an analog of MIBG with prolonged binding to neuroblastoma cells in vitro and retention in the myocardium in vivo.

Duke Scholars

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

February 1997

Volume

38

Issue

2

Start / End Page

330 / 334

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tomography, Emission-Computed
  • Tissue Distribution
  • Radiopharmaceuticals
  • Nuclear Medicine & Medical Imaging
  • Neuroblastoma
  • Mice, Inbred BALB C
  • Mice
  • Iodobenzenes
  • Iodine Radioisotopes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaidyanathan, G., Zhao, X. G., Strickland, D. K., & Zalutsky, M. R. (1997). No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med, 38(2), 330–334.
Vaidyanathan, G., X. G. Zhao, D. K. Strickland, and M. R. Zalutsky. “No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.J Nucl Med 38, no. 2 (February 1997): 330–34.
Vaidyanathan G, Zhao XG, Strickland DK, Zalutsky MR. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med. 1997 Feb;38(2):330–4.
Vaidyanathan, G., et al. “No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.J Nucl Med, vol. 38, no. 2, Feb. 1997, pp. 330–34.
Vaidyanathan G, Zhao XG, Strickland DK, Zalutsky MR. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med. 1997 Feb;38(2):330–334.

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

February 1997

Volume

38

Issue

2

Start / End Page

330 / 334

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Tomography, Emission-Computed
  • Tissue Distribution
  • Radiopharmaceuticals
  • Nuclear Medicine & Medical Imaging
  • Neuroblastoma
  • Mice, Inbred BALB C
  • Mice
  • Iodobenzenes
  • Iodine Radioisotopes